The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Qendri, VenetiaBogaards, Johannes A
Baussano, Iacopo
Lazzarato, Fulvio
Vänskä, Simopekka
Berkhof, Johannes
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment.Published in
Lancet Public Health 2020; 5(11):e592-603PMID
33120045ae974a485f413a2113503eed53cd6c53
10.1016/S2468-2667(20)30209-7
Scopus Count
Collections
Related articles
- Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands.
- Authors: Qendri V, Bogaards JA, Berkhof J
- Issue date: 2017 Jul 15
- Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
- Authors: Jit M, Brisson M, Portnoy A, Hutubessy R
- Issue date: 2014 Jul
- Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
- Authors: Demarteau N, Van Kriekinge G, Simon P
- Issue date: 2013 Aug 20
- The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
- Authors: Sharma M, Sy S, Kim JJ
- Issue date: 2016 May
- Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
- Authors: Wolff E, Elfström KM, Haugen Cange H, Larsson S, Englund H, Sparén P, Roth A
- Issue date: 2018 Aug 16